Clinical Trial

Changes in Electrocardiographic (ECG) Ventricular Repolarization and Transthoracic Impedance Cardiography (ICG) Parameters in Patients with COVID-19 and After the Disease: Persistence and Prognostic Significance of These Changes

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 5, 2024 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to determine the relationship between changes in resting electrocardiography (ECG) ventricular repolarization parameters, transthoracic impedance cardiography (ICG) parameters, and COVID-19, to assess the relationship between ECG changes after COVID-19 and heart rhythm disorders (arrhythmias), cardiovascular events (the onset and exacerbation of cardiovascular diseases), the persistence of changes two years after the illness, and to identify prognostic ventricular repolarization parameters in patients with and after COVID-19. It is expected that the results obtained during the study will help predict long-term cardiovascular complications in these patients, aiming to prevent them by providing recommendations for the long-term monitoring of individuals who have recovered from COVID-19. Additionally, the investigators hope to propose a new ECG ventricular repolarization parameter that could be used in the future for prognostic assessment in patients with other diseases as well.
Trial Details
NCT Number NCT06674278
Lead Sponsor Lithuanian University of Health Sciences
Conditions Post COVID-19, Ventricular Repolarization, Arrhythmias, Impedance Cradiography
Enrollment 215 participants
Start Date 2024-11
Primary Completion 2026-03 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-05